Do you routinely perform next-generation sequencing on otherwise "low-risk" GIST to guide adjuvant therapy?

Yes and no. Defining the molecular make up of a newly diagnosed GIST is recommended and helpful in defining therapy. But the mutational status generally does not dictate adjuvant therapy. That decision is based on clinico-pathologic factors and if "low-risk" based on those criteria, close observatio...